Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1111101

registered interest
date	10/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent estimate his Department has made of the number of NHS prescriptions for medicine in which THC is the dominant ingredient.
tabling member constituency	Newcastle-under-Lyme
tabling member printed	Paul Farrelly
uin	243361
answer	answer is ministerial correction date of answer 17/04/2019 answer text <p>The Department has made no estimate of the number of National Health Service prescriptions for cannabis-based products in which delta-9-tetrahydrocannabinol (THC) is the dominant ingredient.</p><p> </p><p>NHS England is using extant systems to monitor use of the newly rescheduled unlicensed cannabis-based products for medicinal use in England. In England, these systems monitor the number of items dispensed and associated costs in primary care and the volume of products used and associated cost in secondary care. NHS England Controlled Drug Accountable Officers are also collecting local intelligence in both the NHS and independent sector.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 17/04/2019 11:49:19 answering member 4455 label Biography information for Seema Kennedy previous answer version 114110 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
tabling member	1436 label Biography information for Paul Farrelly

1111106

registered interest
date	10/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what advice has been issued to Clinical Commissioning Groups on the criteria for the prescription of medicinal cannabis.
tabling member constituency	Leigh
tabling member printed	Jo Platt
uin	243575
answer	answer is ministerial correction date of answer 17/04/2019 answer text <p>The Chief Medical Officer and NHS England issued a letter on the 31 October 2018, and a supplementary letter on 20 November 2018, providing guidance to clinicians, the National Health Service and independent organisations following the rescheduling of cannabis-based products for medicinal use on 1 November 2018. This signposts interim guidance issued by the Royal College of Physicians, British Paediatric Neurology Association and Association of British Neurologists.</p><p> </p><p>Furthermore, the National Institute for Health and Care Excellence (NICE), has been commissioned to develop guidelines on the prescribing of cannabis-based medicinal products by October 2019. The guidance will focus on four indications: chronic pain, intractable nausea and vomiting, treatment-resistant epilepsy and spasticity. It will be based on the best available international evidence and produced using NICE’s world-renowned process for delivering such guidelines. This guidance will update and replace the interim guidance.</p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 17/04/2019 12:26:52 answering member 4455 label Biography information for Seema Kennedy
tabling member	4673 label Biography information for Jo Platt

1111113

registered interest
date	10/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pregnancy Tests
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 9 April 2019 to Question 239926 on Pregnancy Tests, for what reason previous studies were not considered robust; and what the extensive limitations were.
tabling member constituency	Bolton South East
tabling member printed	Yasmin Qureshi
uin	243382
answer	answer is ministerial correction date of answer 15/04/2019 answer text <p>The Commission on Human Medicines Expert Working Group on Hormone Pregnancy Tests considered that the key limitations of previous studies related to the accuracy of recording of what drug was taken by the women; clarity over the timing of administration during pregnancy; adjustment for confounding factors; selection of controls; and the statistical methodology.</p><p> </p><p>The Expert Group used a quality scoring system to evaluate the quality of each individual study according to a set of seven pre-defined quality criteria. The criteria and score agreed by the Expert Working Group for each study are published in Annex 27 of the final report.</p><p> </p><p>The criteria for selecting members of the Expert Working Group were based on the expertise needed to evaluate all aspects of the questions before the Group and the types of data that would need to be assessed. Membership included those with expertise in pharmaco-epidemiology, including perinatal and paediatric epidemiology, medical statistics, embryology, clinical genetics, gynaecology, reproductive endocrinology, toxicology and pharmacology.</p><p> </p><p>The process for selecting members was in line with established policy for expert groups of the Commission on Human Medicines, with the nominations being agreed by the Commission and endorsed by Ministers.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 243383 question first answered 15/04/2019 14:23:24 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	3924 label Biography information for Yasmin Qureshi

1111114

registered interest
date	10/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Hormone Pregnancy Tests Expert Working Group
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the criteria were for selecting members of the Expert Working Group for Hormone Pregnancy Tests.
tabling member constituency	Bolton South East
tabling member printed	Yasmin Qureshi
uin	243383
answer	answer is ministerial correction date of answer 15/04/2019 answer text <p>The Commission on Human Medicines Expert Working Group on Hormone Pregnancy Tests considered that the key limitations of previous studies related to the accuracy of recording of what drug was taken by the women; clarity over the timing of administration during pregnancy; adjustment for confounding factors; selection of controls; and the statistical methodology.</p><p> </p><p>The Expert Group used a quality scoring system to evaluate the quality of each individual study according to a set of seven pre-defined quality criteria. The criteria and score agreed by the Expert Working Group for each study are published in Annex 27 of the final report.</p><p> </p><p>The criteria for selecting members of the Expert Working Group were based on the expertise needed to evaluate all aspects of the questions before the Group and the types of data that would need to be assessed. Membership included those with expertise in pharmaco-epidemiology, including perinatal and paediatric epidemiology, medical statistics, embryology, clinical genetics, gynaecology, reproductive endocrinology, toxicology and pharmacology.</p><p> </p><p>The process for selecting members was in line with established policy for expert groups of the Commission on Human Medicines, with the nominations being agreed by the Commission and endorsed by Ministers.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 243382 question first answered 15/04/2019 14:23:24 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	3924 label Biography information for Yasmin Qureshi